Quest Diagnostics Incorporated (DGX)

Market Cap	22.98B +26.6%
Revenue (ttm)	11.04B +11.8%
Net Income	988.00M +13.9%
EPS	8.75 +13.8%
Shares Out	110.00M
PE Ratio	23.83
Forward PE	19.60
Dividend	$3.44 (1.65%)
Ex-Dividend Date	Apr 6, 2026

Volume	373,017
Open	207.81
Previous Close	207.43
Day's Range	206.36 - 209.42
52-Week Range	157.20 - 213.20
Beta	0.68
Analysts	Buy
Price Target	208.62 (-0.12%)
Earnings Date	Feb 10, 2026

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 56,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX
• Website: https://www.questdiagnostics.com

Financial Performance

In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.

Analyst Summary

According to 13 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $208.62, which is a decrease of -0.12% from the latest price.

Price Target

$208.62

(-0.12% downside)

Analyst Consensus: Buy